Engineered immune cells take aim at tough T-Cell cancers
NCT ID NCT03081910
First seen Sep 30, 2025 · Last updated Jun 22, 2026 · Updated 34 times
Summary
This early-phase trial tests a new approach for people with certain T-cell blood cancers (leukemia or lymphoma) that have returned. Researchers take a patient's own immune cells (or cells from a past stem cell donor), add a special receptor that targets a protein called CD5 found on cancer cells, and infuse them back. The goal is to see if these engineered cells are safe and can help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T-CELL ACUTE LYMPHOBLASTIC LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Houston Methodist Hospital
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Texas Children's Hospital
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CD5-targeting CAR T cells (genetically modified immune cells)
What this could lead to
If successful, this could point toward a new treatment option for certain T-cell blood cancers that have come back after standard therapy.
What could go wrong
This is a very early phase 1 trial with only 54 participants, so it is not yet known if the treatment is safe or effective. There are risks of serious side effects like cytokine release syndrome.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.